Abionyx Pharma (LTS:0RAG) Interest Income: €0.05 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAG Abionyx Pharma LTS:0RAG
17 GF Score
Price €1.92
GF Value €0.83
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Interest Income?

Abionyx Pharma LTS:0RAG -2.44% 17 Interest Income is €0.05 Mil as of Dec. 2025. GuruFocus rates LTS:0RAG with a GF Score™ of 17/100 and a GF Value™ of €0.83 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Abionyx Pharma's interest income for the six months ended in Dec. 2025 was €0.04 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05 Mil.

Abionyx Pharma Interest Income Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Interest Income Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.06 0.10 0.05

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.03 0.07 0.02 0.04
LTS:0RAG
17GF Score
Abionyx Pharma LTS:0RAG
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of €0.05 Mil mean?
Abionyx Pharma (LTS:0RAG) has a Interest Income of €0.05 Mil as of Dec. 2025. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Abionyx Pharma and its competitors.
Is Abionyx Pharma's Interest Income too high?
Abionyx Pharma's current Interest Income is €0.05 Mil. Overall, Abionyx Pharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Interest Income compare to VRTX and REGN?
Abionyx Pharma's Interest Income of €0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current Interest Income is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.83, compared to a current price of €1.92 — trading 130.8% above its estimated fair value. The current Interest Income is €0.05 Mil. Abionyx Pharma's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current Interest Income is €0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.92 is trading 130.8% above its estimated GF Value™ of €0.83. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0RAG:

  • Interest Income: €0.05 Mil
  • GF Value™: €0.83 vs. price of €1.92 (130.8% above fair value)
  • GF Score™: 17/100 with 4 warning signs

No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Other Exchanges ABNX:France609:Germany
Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
17GF Score

Get the complete analysis for LTS:0RAG

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.92
Price
€0.83
GF Value